Recent Updates — DBVTF

DBV Technologies reported a net loss of $64.5 million ($0.14 per share) for the third quarter ended September 30, 2026, compared to a $33.2 million loss in the prior year period. The company submitted its Biologics License Application (BLA) to the U.S. FDA for VIASKIN Peanut Patch in children aged 4 through 7 years and requested Priority Review. R&D expenses rose to $47.0 million, while sales and marketing costs increased to $5.3 million as the firm scales commercial readiness. DBV holds $165.7 million in cash, funding operations into Q3 2027, though substantial doubt exists regarding its ability to continue as a going concern within twelve months. The company also completed a $50 million equity sale under its ATM program.

DBV Technologies reported Second Quarter and Half-Year 2026 financial results, reporting a net loss of $98.0 million for the six months ended June 30, 2026, compared to $69.0 million for the same period in 2025. The company anticipates an anticipated BLA submission for the VIASKIN Peanut Patch in children aged 4 through 7 years in the third quarter of 2026. As of June 30, 2026, the company holds $174.9 million in cash and cash equivalents, which is expected to support operations into the third quarter of 2027. DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions.